CAS NO: | 2504235-67-8 |
包装 | 价格(元) |
10 mM * 1 mL in DMSO | 电议 |
5mg | 电议 |
10mg | 电议 |
50mg | 电议 |
100mg | 电议 |
生物活性 | Cemsidomide (CFT7455) is an orally activezinc finger transcription factors Ikaros (IKZF1),Aiolos (IKZF3)degrader. Cemsidomide is an anti-cancer agent that binds with high affinity to thecereblonE3 ligase (Kdof 0.9 nM) (WO2022032132A1; Compound 1)[1]. | ||||||||||||||||
IC50& Target[1] |
| ||||||||||||||||
体外研究 (In Vitro) | Cemsidomide promotes the degradation of >75% of steady state IKZF1 in multiple myeloma cells within 1.5 hours at 0.3 nM. The high binding affinity and degradation catalysis of CFT7455 enables potent cell growth inhibition in both previously untreated NCIH929 multiple myeloma cell lines (IC50of 0.071 nM) and NCIH929 cells made resistant to both lenalidomide and pomalidomide (IC50of 2.3 nM)[1]. | ||||||||||||||||
体内研究 (In Vivo) | In mouse xenograft tumor models, Cemsidomide demonstrates dose dependent efficacy from 3 μg/kg/day to 100 μg/kg/day. In several tumor xenografts tested daily dosing of Cemsidomide at dose of 30 μg/kg/day to 100 μg/kg/day led to durable tumor regression[1]. | ||||||||||||||||
Clinical Trial | |||||||||||||||||
分子量 | 469.53 | ||||||||||||||||
性状 | Solid | ||||||||||||||||
Formula | C28H27N3O4 | ||||||||||||||||
CAS 号 | 2504235-67-8 | ||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
储存方式 |
| ||||||||||||||||
溶解性数据 | In Vitro: DMSO : 25 mg/mL(53.24 mM;ultrasonic and warming and heat to 60℃) 配制储备液
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
|